Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has been included in the FTSE4Good Index Series for the 15th consecutive year since its initial inclusion in 2002. The FTSE4Good Index Series is a global index series for socially responsible investment.
The FTSE4Good Index Series identifies companies that better manage environmental, social and governance (ESG) factors into their investment decisions. Of the 14 themes evaluated, Eisai received particularly high scores in “Customer Responsibility” and “Corporate Governance” among others. As of June 2016, a total of 823 companies from around the world have been selected for the FTSE4Good Global Index, including 160 companies from Japan.
Along with being listed in the FTSE4Good Index Series, Eisai is also listed in the Dow Jones Sustainability Asia Pacific Index, another representative index for socially responsible investment.
Eisai’s corporate philosophy is to give first thought to patients and their families and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. Guided by this philosophy, Eisai will continue to develop innovative new drugs and make them available to patients around the world as early as possible to fulfill its social responsibility and secure the trust of stakeholders.
Results of Pivotal TAILOR Study Confirm Addition of Erbitux to FOLFOX Significantly Improves Outcomes in RAS Wild-Type Metastatic Colorectal Cancer
• Phase III study shows response rate of 61.1% for patients treated with
Erbitux plus FOLFOX
• 31% decrease in risk of disease progression and 24% decrease in risk of
death was achieved with addition of Erbitux to FOLFOX
• First prospective study to evaluate Erbitux in RAS wild-type patients
Darmstadt, Germany, July 1, 2016 – Merck, a leading science and technology company, will present data at the ESMO 18th World Congress on Gastrointestinal Cancer (WCGC) from the pivotal Phase III TAILOR study in patients from China, the first prospective trial to evaluate an anti-EGFR antibody in the first-line therapy of patients with RAS wild-type metastatic colorectal cancer (mCRC). The results demonstrate that Erbitux® (cetuximab) plus FOLFOX statistically significantly improves outcomes, including progression-free survival (PFS; primary endpoint), overall survival (OS) and best overall response rate (bORR), compared with FOLFOX alone.(1)
Novo Nordisk and Aarhus University’s Science and Technology faculty today signed a collaboration agreement to strengthen protein technology research and development.
Under the new collaboration, a total of nine PhD students will be offered three-year research scholarships. The research will take place in the leading technological research environments at Science and Technology, Aarhus University, and in Novo Nordisk’s research and development department in Måløv. The Aarhus Novo Nordisk Science and Talent Network programme will run for five years.
“This is the starting point for a stronger collaboration between Aarhus University and Novo Nordisk, which is exploiting the powerful and growing synergy between research and industrial development,” says Niels Chr. Nielsen, dean of the Faculty of Science and Technology, Aarhus University. “The collaboration creates a unique opportunity to focus on talent development while uniting and further developing excellent research environments within the development of protein- and peptide-based medicines at Aarhus University and Novo Nordisk.”
Aarhus University and Novo Nordisk are also seizing the opportunity to initiate collaboration on education. The intention is that students will have the opportunity to combine highly theoretical training directly with practical and industry-relevant problems.
ASTRAZENECA ENTERS LICENSING AGREEMENTS WITH LEO PHARMA IN SKIN DISEASES
Agreement for development and commercialisation of tralokinumab for atopic dermatitis supports sharper focus on main therapy areas
AstraZeneca also licenses European rights to LEO Pharma for brodalumab, a potential new medicine for psoriasis AstraZeneca today announced that it has entered into agreements that support its strategic focus on three main therapy areas; Respiratory, Inflammation and Autoimmunity, Cardiovascular and Metabolic disease and Oncology. The agreements include two of AstraZeneca’s potential new medicines for dermatitis and psoriasis, allowing the Company to further simplify and sharpen focus on innovative new medicines in the main therapy areas.
Cardinal Health Appoints Pamela O. Kimmet Chief Human Resources Officer
PRNewswire/ — Cardinal Health, a global healthcare services and products company, today announced the appointment of Pamela O. Kimmet as Chief Human Resources Officer, effective today. Pam joins the company from Coca-Cola Enterprises, where she was senior vice president, Human Resources. She will report to George S. Barrett, chairman and CEO of Cardinal Health.
Delaware Closes Loophole in Law to Better Protect Emergency Nurses
Emergency Nurses Association praises lawmakers for taking action on a growing problem
(June 30, 2016) – The Emergency Nurses Association applauds Delaware for becoming the latest state to better protect emergency nurses from assault. Gov. Jack Markell signed legislation this week to clarify under what circumstances emergency personnel are covered under the law governing assault in the second degree, which is a felony in Delaware.
Previously, for a violent attack to rise to the level of assault in the second degree against an ambulance operator, a rescue squad member, licensed practical nurse, registered nurse, paramedic or licensed medical doctor, the victim must have been rendering emergency care. read more
Trelleborg’s acquisition of manufacturer of silicone components for the medical device market finalized
Trelleborg has finalized the acquisition of Silicone Fabricators Inc. (SSF), a U.S.-based privately-owned manufacturer of high-precision silicone components for medical technology original equipment manufacturers (OEMs). The acquired company is a significant player in the important and high growth U.S. life sciences market, providing Trelleborg with a strong platform for future development.
SSF is headquartered in Tustin, California, and has production facilities in Tustin and Paso Robles, California, as well as in Elk Rapids, Michigan. Sales amounted to approximately SEK 330 M in 2015. This bolt-on acquisition is part of Trelleborg’s strategy to strengthen its positions in attractive market segments.
Implus Announces Acquisition of Spenco Insoles and 2nd Skin
Implus Acquires Insole Brand and Medical Adhesive Products
DURHAM, N.C.–(EON: Enhanced Online News)–Implus, a provider of athletic, fitness, and outdoor accessories, today announced the acquisition of the Spenco® insole and 2nd Skin® medical adhesive assets of Spenco Medical Corporation. Spenco’s portfolio of insole assets includes the Total Support®, Spenco RX®, and Polysorb® brands. Its medical adhesives unit includes bandages and gels for the treatment of burns, blisters, and hypertrophic and keloid scars.
PENTAX Medical Launches New High-Definition Pulmonology Endoscopy System for Crystal Clear Imaging
New DEFINA system in Pulmonology delivers HD images for clear, fast and more detailed endoscopic visualization of bronchial mucosal structures
HAMBURG, Germany–(BUSINESS WIRE)–PENTAX Medical today announces the launch of a new high-definition (HD) pulmonology endoscopy system in the European, Middle Eastern & African (EMEA) markets. The new DEFINA system in Pulmonology combines a state-of-the art HD processor with i-scan imaging technology and two highly maneuverable HD bronchoscopes. This powerful combination serves to deliver outstanding HD image quality, which subsequently supports clinical outcomes across the complete range of diagnostic and therapeutic applications.read more
Bovie Medical Announces J-Plasma® Sales Channel Partnership with Arteriocyte Medical Systems | EON: Enhanced Online News
- Provides immediate access to plastic surgery market via specialist sales force channel
- Complementary to existing sales efforts while broadening the adoption of J-Plasma® by office-based surgeons
CLEARWATER, Fla.–(EON: Enhanced Online News)–Bovie Medical Corporation (NYSEMKT:BVX), a maker of medical devices and supplies and the developer of J-Plasma®, a patented new surgical product, today announced it had entered into a sales channel partnership Agreement with Arteriocyte Medical Systems, Inc., to sell J-Plasma® to its network of plastic surgeons. read more